Participants to the May 2026 AMA CPT in Boston may recall that Hologic proposed a code for AI Cytology, but the AMA CPT committee rejected it because there was already a decades-old code for computer-assisted cytology, after which they turned back to painting bison on the walls with chalk.
FDA is moving forward, and has just published final paperwork for AI-assisted cervical cytology. 91 FR 69687. Find it here. Find an interesting Linked In article by Michelle Lott here.
The story goes back five years to 2021. On August 27, 2021, FDA received Hologic Inc.’s request for De Novo classification of the Genius Digital Diagnostics System with the Genius Cervical AI algorithm. FDA is codifying the classification of the device by adding 21 CFR 864.3900. The device, FDA finalized in 2024 as DEN210035.
###
AI CORNER
###
FDA Has a Path for AI Cervical Cytology.
CPT Is Still Looking at the Cave Paintings.
Participants at the May 2026 AMA CPT meeting in Boston may recall Hologic’s proposal for a code describing a Pap test with digital diagnosis and algorithmic classification. The AMA’s published summary records the outcome in one word: REJECTED. The discussion pointed back to existing codes for computer-assisted cervical cytology—codes from a rather different technological era. One imagines the committee then returned to painting bison on the cave walls. For more on the 1990s devices, see SIDEBAR at bottom. AMA
FDA, meanwhile, has published something much more interesting. Its November 5, 2026 Federal Register order, 91 FR 69687, establishes 21 CFR 864.3900, a Class II device category for a digital cervical cytology slide imaging system with an artificial intelligence algorithm. This is a final classification order, not new guidance or a new approval. FDA had already granted Hologic’s De Novo request, DEN210035, on January 31, 2024. The new publication codifies that decision and spells out the special controls for this device type. govinfo.gov
The distinction matters beyond Hologic. A successful De Novo request creates an initial classification for a novel device. With a Class II category now in place, a future manufacturer may be able to seek clearance through a 510(k) submission by demonstrating substantial equivalence, while meeting the applicable special controls. FDA has not exempted this device type from 510(k) review. govinfo.gov
What did FDA actually authorize?
Hologic’s Genius system scans ThinPrep Pap test slides, creates digital images, and uses its Cervical AI algorithm to select objects of interest. These appear as a gallery beside an image of the whole cell spot. A qualified cytologist or pathologist reviews the images and makes the interpretation. If the diagnosis remains uncertain after digital review, the labeling calls for direct examination of the glass slide by light microscopy. This is AI-assisted human interpretation, not an autonomous Pap diagnosis. The broader regulatory category also describes possible systems for conventional Pap smears; that broader description should not be mistaken for the specific indications granted to Hologic’s system. accessdata.fda.gov
The De Novo evidence, in brief
FDA received Hologic’s request on August 27, 2021. Its 36-page decision summary describes the imaging and software verification, reproducibility of the AI-selected objects, cell-count testing, a clinical reader study, screening-time analysis, and human-factors testing. The central clinical study used 1,994 slides at four U.S. laboratories.
At each site, three cytologist–pathologist teams reviewed cases by manual microscopy, by the older ThinPrep Imaging System, and with the Genius digital and AI system. There was at least a 14-day interval between review phases. A separate adjudication process supplied the reference diagnoses. The resulting 5,982 reviews were repeat readings of 1,994 slides, not 5,982 separate patients. accessdata.fda.gov
The results are worth reading as a tradeoff:
| Threshold | Sensitivity: Genius vs manual | Specificity: Genius vs manual |
|---|---|---|
| ASC-US or worse | 91.7% vs 90.1% | 91.0% vs 92.2% |
| LSIL or worse | 89.1% vs 84.7% | 91.7% vs 94.1% |
| ASC-H or worse | 87.8% vs 79.6% | 94.2% vs 97.0% |
| HSIL or worse | 81.5% vs 74.0% | 94.8% vs 97.2% |
Sensitivity gains at the LSIL+, ASC-H+, and HSIL+ thresholds were statistically significant. So were the reductions in specificity across the thresholds shown. At HSIL+, FDA characterized the 7.5 percentage-point sensitivity gain as a reduction in false-negative readings from 26% to 18.5% in the study. The lower specificity also matters: more false-positive results can mean additional follow-up. And because the comparison was Genius digital review with AI versus glass-slide review, it does not isolate the AI algorithm’s contribution from the rest of the digital system. accessdata.fda.gov
The workflow result may be just as consequential. Based on its screening-time study, FDA accepted labeling under which a Genius review counts as one-half of a CLIA slide equivalent; a full manual glass review counts as one, and doing both counts as 1.5. That permits up to 200 Genius-only reviews to equal the existing 100-slide ceiling over no less than eight hours. It is a workload-counting rule supported by the submitted data, not a finding that every laboratory will double its actual output. Individual workload limits remain the laboratory technical supervisor’s responsibility. accessdata.fda.gov
Why the new regulation is worth reading
The special controls are unusually concrete. They require documentation of the imaging components and algorithm, analytical testing of its outputs and reproducibility, clinical comparison of intended users with and without AI assistance, screening-time data to set recommended daily workload limits, and human-factors testing. Labeling must explain limitations, training, safeguards, and the user’s responsibility to review the clinically relevant gallery before rendering a diagnosis. FDA is regulating a diagnostic work process, including how much a person can safely do with the system, rather than treating the presence of an algorithm as the clinical result. govinfo.gov
Regulatory consultant Michelle Lott makes a related point in a recent LinkedIn post: a claim about processing twice as many slides needs evidence that intended users can sustain that pace without losing accuracy.
The contrast we can take from these two 2026 events. The AMA CPT in historic Boston saw a Pap service and an old computer-assistance code. FDA examined a specific digital workflow, its diagnostic gains and costs, the people using it, and the evidence needed to support its workload claims. Whether and when coding catches up is a separate question. The FDA's path for artificial intelligencce is already on the books.
###
SIDEBAR
1990's
The earliest FDA approval identified for computer-assisted cervical cytology was the AutoPap 300 QC System, approved on September 29, 1995 for quality-control rescreening of Pap smears. PAPNET followed on November 8, 1995. Both were PMA approvals, so the technology has an FDA history stretching back more than 31 years. www.accessdata.fda.gov
FDA received PAPNET’s PMA application in September 1994. Authorization for initial automated Pap screening came later, when FDA approved that indication for AutoPap on May 5, 1998. www.accessdata.fda.gov









